@Hittman Thank you for your response I acknowledge your point...

@Hittman Thank you for your response

I acknowledge your point but my view is a Roche Genentech style deal is ideally suited to Imugene. Roche’s three best-selling drugs, the cancer medicines Avastin, Herceptin and Rituxan came from Genentech. They were developed by Genentech under the guise and support of Roche. Roche added immeasurable value to Genentech, from first having majority ownership in 1990, to the ultimate acquisition for 46.8 billion USD in 2009. Re: Imugene I’m not being impatient, just stating a fact, that with the support of a strong Big Pharma partner Imugene would be in a position to prevent a repeat of the two years past. Slow trial development, more dilution and a failure in some instances to recruit patients appropriately may have all been avoided. A Nasdaq listing with the support of the prospective Pharma partners shareholders and investors may not have been a bad thing either.

Let’s face it, the ASX and Bell Potter have done Imugene no favours. A Big Pharma taking a stake of 40 to 45% in Imugene negates the need for licensing agreements, which in essence would or could only cover one or two products. Imugene has an extensive suite of products in their pipeline including TIG’s, B cell vaccines and further strains of OV, which could all benefit from additional capital and therein development. I would prefer to see Imugene in a financial position to develop their own vaccines and viruses from within. Such a relationship as that existing between Genentech and Roche in the late 90's would allow that. As hostile as the Genentech Roche relationship became, I'm confident both parties would agree they benefited from such a partnership.

Just on another point, with no disrespect to your post, it would appear no-one around here in Imugene land likes change too much. Everyone is into maintaining status quo. I am of the belief sometimes you have to give away a little to gain a lot. The fact as you suggest many drugs fail in phase 3 is even more reason to attract the support of a large partner. Having a plethora of products in development mitigates unnecessary risk and reliance on individual products, as was Imugene's situation a few years back with Her Vaxx.

On your point of LC saying she is in discussions with Pharmaceuticals, that's all well and good, but Imugene has never entered into one deal of a commercial nature with any company. It's fine to be cautious and indeed optimistic of your products future, but sooner or later you are going to have to step up and be counted. Imugene aren't in a position to take their drugs to market, unlike Big Pharma themselves. So whether we like it or not Imugene are always going to be beholden to Big Pharma. I'd prefer to enter a marriage now whilst we are still relatively young and in a position to stay ahead of the curve, rather than sit back and wait for others to take over us in the cancer treatment race, as Enhertu did with Her Vaxx in recent years.

Speaking of Enhertu, would Daiichi have been able to develop Enhertu as quickly as they are now without the support of AstraZeneca? What do you think? For those unaware both companies in 2019 made an agreement to jointly develop and commercialise trastuzumab deruxtecan (i.e., Enhertu) worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. It was agreed Daiichi Sankyo was solely responsible for manufacturing and supply. Astra Zeneca's dollars funded some pretty decent trials for Enhertu's development. In the DESTINY-PanTumor02 trial they enrolled 267 patients at multiple sites in Asia, Europe and North America.

How many patients has Imugene enrolled during the same time frame in their latest her Vaxx Trial?

IMO there would be lucky to be a tenth of that figure. In June 2022 Her Vaxx's overall survival rates were extremely good. If Imugene had the support of a big brother Her Vaxx and all Imugene's vaccines and viruses could see as many participants as the Destiny Trial did, and hopefully realise clinical trial results commensurate with their scale and size.

It’s all food for thought. I like the Big Pharma partnership concept, as long as Imugene is still steering the bus, in control as it were. If in the end its license agreements, so be it. Thanks again for posting. I appreciate you and everyone commenting, questioning and responding. Apologies if I have been unable to respond to all your questions today..

WMHB

DYOR Opinions only